(Q40470791)

English

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.

scientific article

Statements

Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors. (English)
Heather McCreery
Mitchell Garrison
Johann S DeBono
Christopher B Jones
Eric K Rowinsky

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit